Diagnóstico molecular del cáncer de endometrio

espanolMediante caracterizacion molecular se han identificado una combinacion de biomarcadores fuertemente relacionados con la presencia de cancer de endometrio. Concretamente, se ha desarrollado un test de diagnostico molecular asociado a un algoritmo matematico que, con el analisis de una simple muestra de aspirado endometrial, permite mejorar el diagnostico precoz del cancer de endometrio. Este test, llamado GynEC®-DX, se basa en la interpretacion de cambios moleculares que preceden las alteraciones morfologicas asociadas al cancer de endometrio. La aplicabilidad del test GynEC®-DX, rapido y fiable, mejora por si mismo la precision diagnostica de las pruebas convencionales de biopsia por aspirado o dirigida por histeroscopia, minimizando la posibilidad de resultados no concluyentes, y aporta una informacion de alto valor en determinados perfiles clinicos, que refuerza la confianza en la toma de decision terapeutica y en el proceso de despistaje del cancer de endometrio. Consecuentemente, se reduce el tiempo y el coste medio del diagnostico de cancer, especialmente en 5 perfiles especificos de pacientes caracteristicos: hemorragia uterina anormal de repeticion, ecografia con linea endometrial irregular sin dictamen claro histologico, diagnostico de polipo endometrial, hiperplasia endometrial sin atipias y Sindrome de Lynch. En el presente trabajo se describe el momento de aplicacion del diagnostico molecular, adaptado al algoritmo diagnostico de la SEGO, para cada uno de los citados perfiles de alto riesgo, asi como las ventajas clinicas derivadas EnglishThrough molecular characterization, a combination of biomarkers strongly related to the presence of endometrial cancer has been identified. Specifically, a molecular diagnostic test associated with a mathematical algorithm has been developed which, with the analysis of a simple sample of endometrial aspirate, allows improving the early diagnosis of endometrial cancer. This test, called GynEC®-DX, is based on the interpretation of molecular changes that precede the morphological alterations associated with endometrial cancer. The applicability of this test, called GynEC®-DX, fast and reliable, improves by itself the diagnostic accuracy of conventional aspiration or hysteroscopy-guided biopsy tests, minimizing the possibility of inconclusive results, and provides high value information in certain clinical profiles, which reinforces confidence in therapeutic decision-making and in the endometrial cancer screening process. The combination of GynEC®-DX with histological analysis on endometrial aspirate increases efficacy, sensitivity and Negative Predictive Value. Consequently, time and average cost of cancer diagnosis is reduced, especially in 5 characteristic profiles of abnormal patients: recurrent abnormal uterine bleeding, ultrasound with irregular endometrial line without clear histological opinion, diagnosis of endometrial polyp, endometrial hyperplasia without atypia and Lynch Syndrome. The present work describes the application of endometrial cancer molecular diagnosis, adapted to the SEGO diagnostic algorithm, for the high risk profiles mentioned above, as well as the derived clinical advantages.